Posted by Michael Wonder on 17 Sep 2022
ADC Therapeutics and Sobi announce Zylonta (loncastuximab tesirine) receives positive CHMP opinion in Europe for the treatment of relapsed or refractory diffuse large B-cell lymphoma
16 September 2022 - Approval decision expected in 4Q 2022.
ADC Therapeutics and Sobi today announced the CHMP of the EMA has adopted a positive opinion recommending the marketing authorisation of Zylonta (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
